GLOBAL CANCER BIOMARKERS MARKET RESEARCH AND ANALYSIS 2015-2022
DEFINITION
Cancer biomarkers are one of the ideal ways to diagnose cancer at early stage. These biomarkers can be present in a range of cell lines, tissues and fluids, which results in response to the presence of cancer.
MARKET MOTIVATORS • Rising prevalence of cancer • Growing usage of cancer biomarkers in drug discovery & development • Technological advancements • FDA support for development of biomarkers • Improved accuracy & speed of diagnosis • Increasing research related to cancer biomarkers
MARKET RESTRAINTS
• Low benefit-cost ratio and high capital investment • Lack of regulatory & reimbursement systems • Technical issues related to sample storage and collection
MARKET OPPORTUNITIES
• Rising demand from emerging economies • Growing trend towards personalized medicine • Companion diagnostics
MARKET SEGMENTATION BY BIOMARKER TYPE
Genetic biomarkers
Protein biomarkers
MARKET SEGMENTATION BY TUMOR TYPE
• • • • • •
Lung cancer Prostate cancer Breast cancer Colorectal cancer Cervical cancer Other cancers
MARKET SEGMENTATION
BY APPLICATION
• • • • •
Drug discovery & development Diagnosis Risk assessment Prognostics Others
REGIONAL OVERVIEW
North America
Europe
Asia-Pacific
Rest of the World
MARKET PLAYERS
• • • • •
Merck & co. Inc. QIAGEN N.V. Agilent Technologies, Inc. Novartis International AG Pfizer Inc.
To Be Continued……
FOR MORE DETAILS PLEASE VISIT OUR WEBSITE
Orion Market Research Pvt. Ltd. (OMR Global) 116, Shagun Arcade, Vijay Nagar Square, Indore, Madhya Pradesh India- 452010 +91-7803040404 +1-6467557667 info@omrglobal.com www.omrglobal.com
https://www.omrglobal.com/industry-reports/cancer-biomarkers-market/